Ensartinib FDA Approval Status
FDA Approved: No
Generic name: ensartinib
Company: Xcovery Holdings, Inc.
Treatment for: Non-Small Cell Lung Cancer
Ensartinib is an Anaplastic Lymphoma Kinase (ALK) inhibitor in development for the treatment of adult patients with metastatic ALK-positive non-small cell lung cancer (NSCLC).
Development timeline for ensartinib
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
